Clinical Trials Logo

Nasopharyngeal Carcinoma clinical trials

View clinical trials related to Nasopharyngeal Carcinoma.

Filter by:

NCT ID: NCT06019130 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Nivolumab in Children and Adults With Nasopharyngeal Carcinoma

NPC-Nivo
Start date: January 10, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess whether the addition of the immune checkpoint inhibitor Nivolumab to induction chemotherapy will increase the percentage of patients with a complete response on MRI and PET after 3 cycles of induction therapy.

NCT ID: NCT06017895 Recruiting - Clinical trials for Swallowing-induced Pain

Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to explore the effectiveness and adverse reactions of doxepin solution spray for alleviation of stubborn breakthrough pain induced by swallowing in patients receiving radiotherapy for nasopharyngeal carcinoma.

NCT ID: NCT05994170 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma

CTVp1-NPC
Start date: August 4, 2023
Phase: N/A
Study type: Interventional

To evaluate the long-term local control, survival rate, acute and late radiation related toxicities, quality of life after reducing high risk primary tumor clinical target volumes (CTVp1) in non-metastatic nasopharyngeal carcinoma treated with IMRT.

NCT ID: NCT05983432 Recruiting - Breast Cancer Clinical Trials

Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Start date: August 8, 2023
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

NCT ID: NCT05981157 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Anrotinib and Tirelizumab in First-line Treatment of RM-NPC

Start date: June 1, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective phase II clinical trial to evaluate the efficacy and safety of Anrotinib and Tirelizumab as a first-line treatment in patients with advanced recurrent or metastatic nasopharyngeal carcinoma.

NCT ID: NCT05979961 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

Start date: September 7, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare concurrent chemoradiotherapy (CCRT) alone with induction chemotherapy (gemcitabine+cisplatin) plus CCRT in patients with low-risk locoregionally advanced nasopharyngeal carcinoma(NPC).

NCT ID: NCT05956587 Recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Start date: January 29, 2024
Phase: Phase 2
Study type: Interventional

Phase II: To explore the efficacy, safety and tolerability of BL-B01D1+SI-B003 in patients with locally advanced or metastatic non-small cell lung cancer and nasopharyngeal carcinoma, and to further explore the optimal dose and mode of combination.

NCT ID: NCT05955105 Recruiting - Ovarian Cancer Clinical Trials

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Start date: July 25, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open-label, phase Ib/IIa study. The first part of the study will evaluate the safety, tolerability and preliminary efficacy of ILB2109 and Toripalimab in patients with locally advanced or metastatic solid malignancies. The second part of the study will evaluate the efficacy of ILB2109 and Toripalimab in patients with selected advanced solid malignancies.

NCT ID: NCT05949749 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

A Retrospective Study Reveals the Relationship Between gp42-IgG Epitopes and EBV-associated NPC

Start date: August 25, 2023
Phase:
Study type: Observational

Epstein-barr virus (EBV) infection is a necessary factor of nasopharyngeal carcinoma (NPC). The incidence of NPC in endemic regions reaches 24.60/100,000 people, far higher than that of the worldwide average. However, no EBV prophylactic vaccines is clinically available so far, which is largely hampered by the difficulties in selecting optimal vaccine design target out of 13 glycoproteins on the surface of EBV. In this study, we utilized humanized gp42-IgG antibodies to explore the dominant epitopes of gp42, one of the functional EBV glycoproteins during virus entry, to facilitate prophylactic vaccine design.

NCT ID: NCT05941741 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Start date: January 10, 2024
Phase: Phase 3
Study type: Interventional

This is a multi-center, open-label, randomized controlled phase III clinical trial in primary diagnosed loco-regionally advanced nasopharyngeal carcinoma (NPC) patients. The purpose of this study is to evaluate the efficacy of induction chemotherapy (IC) combined with low-dose radiation and immune checkpoint inhibitor (ICI) followed by concurrent chemoradiotherapy (CCRT) versus IC+CCRT, and compare the treatment-related adverse events and quality of life in two groups.